Literature DB >> 12038972

Prostaglandin receptors: advances in the study of EP3 receptor signaling.

Noriyuki Hatae1, Yukihiko Sugimoto, Atsushi Ichikawa.   

Abstract

Prostaglandin (PG) E(2) produces a broad range of physiological and pharmacological actions in diverse tissues through specific receptors on plasma membranes for maintenance of local homeostasis in the body. PGE receptors are divided into four subtypes, EP1, EP2, EP3, and EP4, which have been identified and cloned. These EP receptors are members of the G-protein coupled receptor family. Among these subtypes, the EP3 receptor is unique in its ability to couple to multiple G proteins. EP3 receptor signals are primarily involved in inhibition of adenylyl cyclase via G(i) activation, and in Ca(2+)-mobilization through G(beta)(gamma) from G(i). Along with G(i) activation, the EP3 receptor can stimulate cAMP production via G(s) activation. Recent evidence indicates that the EP3 receptor can augment G(s)-coupled receptor-stimulated adenylyl cyclase activity, and can also be coupled to the G(13) protein, resulting in activation of the small G protein Rho followed by morphological changes in neuronal cells. This article focuses on recent studies on the novel pathways of EP3 receptor signaling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038972     DOI: 10.1093/oxfordjournals.jbchem.a003165

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  44 in total

1.  Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists.

Authors:  Winnie W C Shum; Geng-Yun Le; Robert L Jones; Alison M Gurney; Yasuharu Sasaki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

2.  PGE(2) is a UVR-inducible autocrine factor for human melanocytes that stimulates tyrosinase activation.

Authors:  Renny J Starner; Lindy McClelland; Zalfa Abdel-Malek; Alex Fricke; Glynis Scott
Journal:  Exp Dermatol       Date:  2010-05-25       Impact factor: 3.960

Review 3.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

5.  Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2015-05       Impact factor: 3.386

6.  Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors.

Authors:  Y Ikeda-Matsuo; H Tanji; A Ota; Y Hirayama; S Uematsu; S Akira; Y Sasaki
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

7.  Multiple roles of the PGE2 -EP receptor signal in vascular permeability.

Authors:  K Omori; T Kida; M Hori; H Ozaki; T Murata
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

8.  Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266.

Authors:  J Günther; K Schulte; D Wenzel; B Malinowska; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

9.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

10.  The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer.

Authors:  R L Konger; S D Billings; N C Prall; T M Katona; S C Dasilva; C R J Kennedy; S Badve; S M Perkins; P T Lacelle
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-07-22       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.